Temocillin in cystic fibrosis: A retrospective pilot study

Lisa Kent; Judy Bradley; Megan France; Gerd Doring; Stephane Carryn; Ian Bradbury; Jackie Rendall; Andrew Jones; J. Stuart Elborn

doi:10.1016/j.jcf.2008.06.005

Temocillin in cystic fibrosis: A retrospective pilot study

Lisa Kent, Judy Bradley, Megan France, Gerd Doring, Stephane Carryn, Ian Bradbury, Jackie Rendall, Andrew Jones, J. Stuart Elborn

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p

Original language	English
Pages (from-to)	551-554
Journal	Journal of Cystic Fibrosis
Volume	7
Issue number	6
DOIs	https://doi.org/10.1016/j.jcf.2008.06.005
Publication status	Published (in print/issue) - Nov 2008

Keywords

Temocillin
Burkholderia cepacia complex
Pseudomonas aeruginosa

Access to Document

10.1016/j.jcf.2008.06.005

http://www.cysticfibrosisjournal.com/article/S1569-1993(08)00097-0/abstract

Cite this

@article{6c98df672d8340b28e5c4874d4dfee51,

title = "Temocillin in cystic fibrosis: A retrospective pilot study",

abstract = "Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p",

keywords = "Temocillin, Burkholderia cepacia complex, Pseudomonas aeruginosa",

author = "Lisa Kent and Judy Bradley and Megan France and Gerd Doring and Stephane Carryn and Ian Bradbury and Jackie Rendall and Andrew Jones and Elborn, {J. Stuart}",

year = "2008",

month = nov,

doi = "10.1016/j.jcf.2008.06.005",

language = "English",

volume = "7",

pages = "551--554",

journal = "Journal of Cystic Fibrosis",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Temocillin in cystic fibrosis: A retrospective pilot study

AU - Kent, Lisa

AU - Bradley, Judy

AU - France, Megan

AU - Doring, Gerd

AU - Carryn, Stephane

AU - Bradbury, Ian

AU - Rendall, Jackie

AU - Jones, Andrew

AU - Elborn, J. Stuart

PY - 2008/11

Y1 - 2008/11

N2 - Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p

AB - Background: Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation.MethodsA retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within ±1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV1%, FVC%).ResultsTwenty six patients had received temocillin. Baseline values of FEV1% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV1% increased by 7.12(11.67)% after TIV (p

KW - Temocillin

KW - Burkholderia cepacia complex

KW - Pseudomonas aeruginosa

U2 - 10.1016/j.jcf.2008.06.005

DO - 10.1016/j.jcf.2008.06.005

M3 - Article

VL - 7

SP - 551

EP - 554

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 6

ER -

Temocillin in cystic fibrosis: A retrospective pilot study

Abstract

Keywords

Access to Document

Fingerprint

Cite this